FDA approves TALZENNA plus XTANDI for HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer October 28, 2026
European Commission approves TECVAYLI (teclistamab) monotherapy for relapsed/refractory multiple myeloma October 27, 2026
FDA grants traditional approval for Keytruda or Keytruda Qlex for unresectable or metastatic TMB-H solid tumors with updated indication October 27, 2026
European Commission Approves KEYTRUDA® + Padcev® as Perioperative Treatment for Adults With Resectable MIBC October 27, 2026
FDA Expands ANKTIVA® Approval for BCG-Unresponsive NMIBC to Cover Both Papillary and CIS Disease October 20, 2026
Jemperli (dostarlimab) approved in US for adults with MSI-H/dMMR locally advanced rectal cancer October 20, 2026
TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer October 14, 2026
FDA approved adjuvant Tecentriq and Tecentriq Hybreza in combination with a fluoropyrimidine and oxaliplatin for the treatment of stage III dMMR colon cancer October 14, 2026
Jaypirca (pirtobrutinib) receives expanded indication from US FDA for 1L CLL/SLL patients October 6, 2026
FDA Approves Lyrfigtu (Lirafugratinib) for 2L Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement Treatment Option October 1, 2026
FDA approves BRAVNETSA™ (lutetium Lu 177 dotatate) for patients with SSR+ve GEP-NETs, including foregut, midgut, and hindgut NEC tumors October 1, 2026
FDA Approves WELIREG + LENVIMA for Certain Previously Treated Adult Patients With clear cell RCC October 1, 2026
FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer September 22, 2026
KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for SubQ Administration for All KEYTRUDA Indications Approved in Japan September 22, 2026
FDA approves BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs September 22, 2026
Etcamah + CDK4/6 inhibitor combo approved in the US for 1L advanced HR-positive breast cancer September 9, 2026
FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab + Chemo in 1L HER2+ Advanced Gastroesophageal Adenocarcinoma September 2, 2026
European Commission approves TECVAYLI (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma August 25, 2026
FDA Grants Accelerated Approval to ZENBEXUS in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma August 20, 2026
NMPA approves felzartamab (Jingfei) + lenalidomide and dexamethasone for treating multiple myeloma patients who have received at least one prior line of therapy August 20, 2026
Ivonescimab + Chemo Approved in China by NMPA for 1L Treatment of Patients with Squamous NSCLC August 20, 2026
FDA grants Accelerated Approval to TUDRIQEV + Nivolumab combo for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen August 11, 2026
